The distribution of FDG at PET examinations constitutes a relative mechanism: significant effects at activity quantification in patients with a high muscular uptake
Authors:
- 14 August 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 39 (11) , 1685-1690
Abstract
At 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) examinations a high tracer uptake of the skeletal muscles is sometimes encountered which can lead to reduced uptake in pathological lesions. This was evaluated in retrospect in patients being recalled for a repeat examination after reducing the muscular uptake. Ten patients with increased muscular tracer uptake were examined with FDG PET/CT on two occasions with a mean of 6 days. All patients showed at least one pathological lesion with increased tracer uptake. The muscular uptake was reduced at the second examination by informing the patient to refrain from physical activity together with pretreatment with diazepam. The maximum standardized uptake value (SUVmax) of the pathological lesion and SUVmean of certain skeletal muscles, liver, spleen, lungs, blood and certain bone marrow portions were calculated. In all patients, the muscular uptake was reduced to a normal level at visual evaluation as well as at comparison of SUVs with 25 consecutive clinical patients exhibiting a normal FDG distribution (p max increased from 2.4 to 3.7 (54 %) between the examinations (p max to the activity of any of the reference tissues/organs there was no significant difference between the studies. The distribution of FDG constitutes a relative mechanism. This must be especially considered at longitudinal examinations in the same patient at therapy evaluations. In examinations with a somehow distorted general distribution of the activity, it may be more relevant to relate the lesion activity to a reference tissue/organ than relying on SUV assessments.Keywords
This publication has 20 references indexed in Scilit:
- Repeatability of Metabolically Active Volume Measurements with18F-FDG and18F-FLT PET in Non–Small Cell Lung CancerJournal of Nuclear Medicine, 2010
- Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal MalignanciesJournal of Nuclear Medicine, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Standards for PET Image Acquisition and Quantitative Data AnalysisJournal of Nuclear Medicine, 2009
- The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studiesNuclear Medicine Communications, 2008
- Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSFJournal of Nuclear Medicine, 2007
- Diaphragmatic and Crural FDG Uptake in Hyperventilating Patients: A Rare Pattern Important to RecognizeClinical Nuclear Medicine, 2004
- Reproducibility of metabolic measurements in malignant tumors using FDG PET.1999
- Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.Radiology, 1995